Bagsværd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market with a full portfolio of glucagon-like peptide 1 (GLP-1) receptor agonists, modern ...

Innovation, artificial intelligence, drug costs and shortages, private equity interests, and more left their mark in ...

FDA Approves First Generic of Once-Daily GLP-1 Injection to Lower Blood Sugar in Patients with Type 2 Diabetes ...

Nearly half of US adults admit they’d take one of the newer, injectable weight loss drugs, but that number falls ...

GLP-1 modulators, formally known as glucagon-like peptide-1 receptor agonists, function by enhancing insulin secretion, ...

Liraglutide injection is now approved for adult and pediatric patients ages 10 and up, proving another option amid the GLP-1 ...

In 2024, the most-read articles published in Population Health, Equity & Outcomes (PHEO) highlighted the promise of ...

One lawmaker said the CT Department of Social Services told him the agency wasn’t paying for FDA-approved drugs because of ...

Body mass index (BMI) and obesity prevalence declined in the United States in 2023, according to a research letter published ...

Zepbound is the first medication approved to treat people with obstructive sleep apnea, said Sailly Seymor, director of FDA's ...

Today, the U.S. Food and Drug Administration approved the first generic referencing Victoza (liraglutide injection) 18 ...

Takers of GLP-1 are reportedly going on a "holiday pause" to enjoy meal centric family celebrations. Here, an MD breaks down the risks of the trend.